Similar to advanced clinical breast cancers [9, 10], inhibition of the PD axis as a monotherapy had little effect on tumor growth or survival (Fig. 1C-F), consistent with the low levels of infiltrating CD8+ T cells and PD-L1 expression in these immunosuppressed tumors. This evidence concerns the gene CD8A and neoplasm.